ID   Me15392
AC   CVCL_C604
SY   Me-15392; Me 15392; 15392; 15392M
DR   cancercelllines; CVCL_C604
DR   Cosmic; 2163824
DR   ESTDAB; ESTDAB-114
DR   Wikidata; Q54904922
RX   DOI=10.13130/grazia-giulia_phd2016-02-18;
RX   PubMed=9973437;
RX   PubMed=15592718;
RX   PubMed=22553342;
RX   PubMed=23851445;
RX   PubMed=25576923;
CC   HLA typing: A*11:01,03:01; B*40:01,14:01; DPB1*10:01,13:01; DQB1*05:01; DRB1*01:01,10:01 (PubMed=15592718).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
ST   Source(s): ESTDAB=ESTDAB-114
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 9
ST   D3S1358: 17
ST   D5S818: 14
ST   D7S820: 9,10
ST   FGA: 22
ST   TH01: 6
ST   TPOX: 11
ST   vWA: 15
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_HE34 ! LCL15392
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 19-12-24; Version: 18
//
RX   DOI=10.13130/grazia-giulia_phd2016-02-18;
RA   Grazia G.;
RT   "Co-targeting of oncogenic and death receptors pathways in human
RT   melanoma: pre-clinical rationale for a pro-apoptotic and anti-angiogenic
RT   strategy.";
RL   Thesis PhD (2015); Universita degli studi di Milano; Milano; Italy.
//
RX   PubMed=9973437; DOI=10.4049/jimmunol.162.3.1739;
RA   Castelli C., Tarsini P., Mazzocchi A., Rini F., Rivoltini L.,
RA   Ravagnani F., Gallino F., Belli F., Parmiani G.;
RT   "Novel HLA-Cw8-restricted T cell epitopes derived from
RT   tyrosinase-related protein-2 and gp100 melanoma antigens.";
RL   J. Immunol. 162:1739-1748(1999).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5; PMCID=PMC11032966;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello Osuna F., Dodi I.A.,
RA   Lopez-Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=22553342; DOI=10.1158/1078-0432.CCR-11-2232; PMCID=PMC3426233;
RA   Tassi E., Zanon M., Vegetti C., Molla A., Bersani I., Perotti V.,
RA   Pennati M., Zaffaroni N., Milella M., Ferrone S., Carlo-Stella C.,
RA   Gianni A.M., Mortarini R., Anichini A.;
RT   "Role of Apollon in human melanoma resistance to antitumor agents that
RT   activate the intrinsic or the extrinsic apoptosis pathways.";
RL   Clin. Cancer Res. 18:3316-3327(2012).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//
RX   PubMed=25576923; DOI=10.18632/oncotarget.2995; PMCID=PMC4413617;
RA   Loria R., Bon G., Perotti V., Gallo E., Bersani I., Baldassari P.,
RA   Porru M., Leonetti C., Di Carlo S., Visca P., Brizzi M.F.,
RA   Anichini A., Mortarini R., Falcioni R.;
RT   "Sema6A and Mical1 control cell growth and survival of BRAFV600E human
RT   melanoma cells.";
RL   Oncotarget 6:2779-2793(2015).
//